Cynthia Collins has more than four decades of experience in the pharmaceutical and biotech industry. She currently serves as Executive Chair and interim CEO of Nutcracker Therapeutics, a contract, research, development and manufacturing organization with a next generation RNA precision manufacturing platform. Previously, she was the CEO of Editas Medicine from 2019 to 2021, where the first clinical trial administration of an in vivo CRISPR gene editing therapy took place under her leadership. Ms. Collins’ previous executive roles in biopharma include CEO of Human Longevity; CEO/general manager of various life science businesses at GE Healthcare; president and CEO of GenVec; group vice president at Beckman Coulter; CEO and president of Sequoia Pharmaceuticals; and president of Global Oncology at Baxter Healthcare. Earlier in her career, she served as President of Clinical Micro Sensors, Inc., then a subsidiary of Motorola. She began her career in various operating roles with Abbott Laboratories. Ms. Collins is a board member of Certara (CERT), MaxCyte (MXCT), DermTech (DMTK), Draper Laboratories, Alanis Therapeutics and Foundation for mRNA Medicines. She received her B.S. degree in microbiology from the University of Illinois, Urbana, and earned an M.B.A. from The University of Chicago Booth School of Business.